Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.

被引:691
作者
Bartelink, H
Horiot, J
Poortmans, P
Struikmans, H
Van den Bogaert, W
Barillot, I
Fourquet, A
Borger, J
Jager, J
Hoogenraad, W
Collette, L
Pierart, M
机构
[1] Netherlands Canc Inst, Dept Radiat Oncol, NL-1066 CX Amsterdam, Netherlands
[2] Dr Bernard Verbeeten Inst, Dept Radiat Oncol, Tilburg, Netherlands
[3] Univ Utrecht Hosp, Dept Radiat Oncol, Utrecht, Netherlands
[4] Radiotherapeut Inst Limburg, Dept Radiat Oncol, Heerlen, Netherlands
[5] St Radboud Hosp, Joint Ctr Radiotherapy Arnhem Nijmegen, Dept Radiat Oncol, Nijmegen, Netherlands
[6] Ctr Georges Francois Leclerc, Dept Radiat Oncol, Dijon, France
[7] Inst Curie, Dept Radiat Oncol, Paris, France
[8] Univ Hosp Gasthuisberg, Dept Radiat Oncol, B-3000 Louvain, Belgium
[9] European Org Res Treatment Canc, Brussels, Belgium
关键词
D O I
10.1056/NEJMoa010874
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Radiotherapy prevents local recurrence of breast cancer after breast-conserving surgery. We evaluated the effect of a supplementary dose of radiation to the tumor bed on the rates of local recurrence among patients who received radiotherapy after breast-conserving surgery for early breast cancer. Methods: After lumpectomy and axillary dissection, patients with stage I or II breast cancer received 50 Gy of radiation to the whole breast in 2-Gy fractions over a five-week period. Patients with a microscopically complete excision were randomly assigned to receive either no further local treatment (2657 patients) or an additional localized dose of 16 Gy, usually given in eight fractions by means of an external electron beam (2661 patients). Results: During a median follow-up period of 5.1 years, local recurrences were observed in 182 of the 2657 patients in the standard-treatment group and 109 of the 2661 patients in the additional-radiation group. The five-year actuarial rates of local recurrence were 7.3 percent (95 percent confidence interval, 6.8 to 7.6 percent) and 4.3 percent (95 percent confidence interval, 3.8 to 4.7 percent), respectively (P<0.001), yielding a hazard ratio for local recurrence of 0.59 (99 percent confidence interval, 0.43 to 0.81) associated with an additional dose. Patients 40 years old or younger benefited most; at five years, their rate of local recurrence was 19.5 percent with standard treatment and 10.2 percent with additional radiation (hazard ratio, 0.46 [99 percent confidence interval, 0.23 to 0.89]; P=0.002). At five years in the age group 41 to 50 years old, no differences were found in rates of metastasis or overall survival (which were 87 and 91 percent, respectively). Conclusions: In patients with early breast cancer who undergo breast-conserving surgery and receive 50 Gy of radiation to the whole breast, an additional dose of 16 Gy of radiation to the tumor bed reduces the risk of local recurrence, especially in patients younger than 50 years of age.
引用
收藏
页码:1378 / 1387
页数:10
相关论文
共 37 条
[31]  
VANTIENHOVEN G, 1992, RADIOTHER ONCOL S, V24, pS35
[32]   BREAST-CONSERVATION IS A SAFE METHOD IN PATIENTS WITH SMALL CANCER OF THE BREAST - LONG-TERM RESULTS OF 3 RANDOMIZED TRIALS ON 1,973 PATIENTS [J].
VERONESI, U ;
SALVADORI, B ;
LUINI, A ;
GRECO, M ;
SACCOZZI, R ;
DELVECCHIO, M ;
MARIANI, L ;
ZURRIDA, S ;
RILKE, F .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) :1574-1579
[33]   RADIOTHERAPY AFTER BREAST-PRESERVING SURGERY IN WOMEN WITH LOCALIZED CANCER OF THE BREAST [J].
VERONESI, U ;
LUINI, A ;
DELVECCHIO, M ;
GRECO, M ;
GALIMBERTI, V ;
MERSON, M ;
RILKE, F ;
SACCHINI, V ;
SACCOZZI, R ;
SAVIO, T ;
ZUCALI, R ;
ZURRIDA, S ;
SALVADORI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (22) :1587-1591
[34]   Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials [J].
Voogd, AC ;
Nielsen, M ;
Peterse, JL ;
Blichert-Toft, M ;
Bartelink, H ;
Overgaard, M ;
van Tienhoven, G ;
Andersen, KW ;
Sylvester, RJ ;
van Dongen, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1688-1697
[35]   The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial [J].
Vrieling, C ;
Collette, L ;
Fourquet, A ;
Hoogenraad, WJ ;
Horiot, JC ;
Jager, JJ ;
Pierart, M ;
Poortmans, PM ;
Struikmans, H ;
Van der Hulst, M ;
Van der Schueren, E ;
Bartelink, H .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (03) :677-685
[36]   The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial [J].
Vrieling, C ;
Collette, L ;
Fourquet, A ;
Hoogenraad, WJ ;
Horiot, JC ;
Jager, JJ ;
Pierart, M ;
Poortmans, PM ;
Struikmans, H ;
Maat, B ;
Van Limbergen, E ;
Bartelink, H .
RADIOTHERAPY AND ONCOLOGY, 2000, 55 (03) :219-232
[37]  
Whelan TJ, 1998, CAN MED ASSOC J, V158, pS35